Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 14/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 3/20 | 0.46 |
| ▸ | AHCY | P23526 | 1/20 | 0.45 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19563037 | 0.89 | ADK (0.48) | ADKPRMT5WDR77METTL3AHCY | |
| SCHEMBL191943 | 0.89 | ADK (0.48) | ADKPRMT5WDR77METTL3AHCY | |
| SCHEMBL192357 | 0.82 | PRMT5 (0.45) | ADKPRMT5WDR77METTL3UBA6 | |
| SCHEMBL17875227 | 0.81 | NAE1 (0.62) | UBA6 | |
| SCHEMBL192379 | 0.81 | NAE1 (0.62) | UBA6 | |
| SCHEMBL13314384 | 0.77 | ADK (0.53) | ADKPRMT5WDR77METTL3 | |
| SCHEMBL25048671 | 0.77 | UBA6 (0.42) | PRMT5WDR77UBA6 | |
| SCHEMBL10186224 | 0.77 | UBA6 (0.42) | PRMT5WDR77UBA6 | |
| SCHEMBL18572688 | 0.77 | PRMT5 (0.62) | PRMT5WDR77METTL3 | |
| SCHEMBL17875209 | 0.75 | UBA6 (0.52) | METTL3UBA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | MILLENNIUM PHARM INC (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | ADK 1068/4885PRMT5 870/4885WDR77 2632/4885 |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | ADK 1068/4885PRMT5 870/4885WDR77 2632/4885 |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | ADK 1068/4885PRMT5 870/4885WDR77 2632/4885 |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | ADK 1068/4885PRMT5 870/4885WDR77 2632/4885 |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | RNASE1, ECE1, CES1 | ADK 1026/4885PRMT5 822/4885WDR77 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.